Table 1 Baseline characteristics of 26 randomized controlled trials in the meta-analysis (number = 14,060)
Authors/year/phase | Histology | Patients enrolled | Treatment aim | Median age, years | Median duration, weeks | Median PFS, m | Median OS, m | Number for analysis | Severe infections | Reported infectious events |
|---|---|---|---|---|---|---|---|---|---|---|
Burtness B. et al ./2005/III | Head and neck cancer | 117 | Cetuximab + DDP | 60.6 | 4.5 | 4.2 | 9.2 | 58 | 15 | Infections |
|  |  |  | Placebo + DDP | 58.3 | 3 | 2.7 | 8 | 58 | 10 | |
Bonner J.A . et al ./2006/III | Head and neck cancer | 424 | Cetuximab + radiotherapy | 56 | 8 | 24.4 | 49 | 208 | 1 | Infections |
| Â | Â | Â | Radiotherapy | 58 | NR | 14.9 | 29.3 | 212 | 1 | |
Jonker D. J. et al ./2007/III | CRC | 572 | Cetuximab + BSC | 63 | 8.1 | NR | 6.1 | 288 | 37 | Infections |
| Â | Â | Â | BSC | 63.6 | NR | NR | 4.6 | 274 | 15 | |
Borner M. et al ./2008/II | CRC | 74 | Cetuximab + oxaliplatin + capecitabine | 60 | 18 | 7.2 | 20.5 | 37 | 0 | Febrile neutropenia |
|  |  |  | Oxaliplatin + capecitabine | 63 | 18 | 5.8 | 16.5 | 37 | 0 | |
Rosell R. et al ./2008/II | NSCLC | 86 | Cetuximab + NVB + DDP | 58 | 13.6 | 5 | 8.3 | 42 | 7 | Infections |
|  |  |  | NVB + DDP | 57 | 12 | 4.6 | 7.3 | 43 | 2 | |
Sobrero A.F. et al ./2008/III | CRC | 1298 | Cetuximab + irinotecan | 61 | 14 | 4 | 10.7 | 638 | 49 | Febrile neutropenia |
| Â | Â | Â | Irinotecan | 62 | 13.1 | 2.6 | 10 | 629 | 39 | |
Vermorken J.B. et al. /2008/III | Head and neck cancer | 422 | Cetuximab + platinum + FU | 56 | 18 | 5.6 | 10.1 | 219 | 28 | Febrile neutropenia, pneumonia, sepsis |
|  |  |  | Platinum + FU | 57 | 15 | 3.3 | 7.4 | 215 | 15 | |
Lienbaum R. et al ./2009/II | NSCLC | 64 | Cetuximab + PTX | NR | 16 | 3.4 | NR | 30 | 1 | Infections |
|  |  |  | Bortezomib + PTX | NR | 8 | 1.9 | NR | 29 | 1 | |
Pirker R. et al ./2009/III | NSCLC | 1125 | Cetuximab + NVB + DDP | 59 | 18 | NR | 11.3 | 548 | 129 | Febrile neutropenia, sepsis |
|  |  |  | NVB + DDP | 60 | 14 | NR | 10.1 | 562 | 90 | |
Tol J. et al ./2009/III | CRC | 755 | Cetuximab + capecitabine + oxaliplatin + Bev | 62 | 30 | 10.7 | 20.3 | 366 | 22 | Infections |
|  |  |  | Capecitabine + oxaliplatin + Bev | 62 | 25.7 | 9.4 | 19.4 | 366 | 25 | |
Lynch T.J. et al ./2010/III | NSCLC | 676 | Cetuximab + chemotherapy | 64 | 13 | 4.4 | 9.69 | 325 | 15 | Febrile neutropenia |
| Â | Â | Â | Chemotherapy | 65 | 12 | 4.24 | 8.38 | 320 | 11 | |
Govindan R. et al ./2011/II | NSCLC | 101 | Cetuximab + chemoradiotherapy | 66 | NR | 12.3 | 22.2 | 53 | 9 | Febrile neutropenia, pneumonia, |
| Â | Â | Â | Chemoradiotherapy | 65 | NR | 12.6 | 22.4 | 50 | 10 | |
Alberts S.R. et al ./2012/III | CRC | 2686 | Cetuximab + FOLFOX | NR | NR | NR | NR | 931 | 96 | Infections, febrile neutropenia, pneumonia |
| Â | Â | Â | FOLFOX | NR | NR | NR | NR | 894 | 45 | |
Dewdney A. et al ./2012/II | CRC | 165 | Cetuximab + capecitabine + oxaliplatin + radiotherapy | 65 | NR | NR | NR | 83 | 1 | Febrile neutropenia |
|  |  |  | Capecitabine + oxaliplatin + radiotherapy | 61 | NR | NR | NR | 81 | 1 | |
Saltz L. et al ./2012/III | CRC | 247 | Cetuximab + Bev + FOLFOX | 63.2 | NR | 8.3 | 19.5 | 121 | 1 | Sepsis |
|  |  |  | Bev + FOLFOX | 61.2 | NR | 11 | 21.3 | 118 | 1 | |
Baselga J. et al ./2013/II | MBC | 181 | Cetuximab + DDP | 53 | 13.6 | 3.7 | 12.9 | 114 | 2 | Sepsis |
| Â | Â | Â | DDP | 52 | 13.1 | 1.5 | 9.4 | 57 | 0 | |
Kim E.S. et al ./2013/III | NSCLC | 605 | Cetuximab + Pemetrexed | 64 | NR | 2.9 | 6.9 | 292 | 35 | Infections, lung infections, sepsis |
| Â | Â | Â | Pemetrexed | 65 | NR | 2.8 | 7.8 | 289 | 23 | |
Burtness B. et al ./2014/II | Pancreatic cancer | 87 | Cetuximab + Doc + irinotecan | 60 | 16.5 | 4.5 | 6.5 | 45 | 5 | Febrile neutropenia, infections |
|  |  |  | Doc + irinotecan | 60 | 14.5 | 3.9 | 5.3 | 46 | 4 | |
Huang J. et al ./2014/III | CRC | 146 | Cetuximab + FOLFIRI | 57 | NR | NR | NR | 40 | 3 | Infections, febrile neutropenia |
| Â | Â | Â | FOLFIRI | 59 | NR | NR | NR | 106 | 3 | |
Hussain M. et al ./2014/II | Urothelial carcinoma | 88 | Cetuximab + GEM + DDP | 60.9 | 21.4 | 7.6 | 14.3 | 59 | 7 | Infections, pneumonia |
|  |  |  | GEM + DDP | 65.8 | 21.4 | 8.5 | 17.4 | 28 | 3 | |
van den Heuval M.M. et al. /2014/II | NSCLC | 102 | Cetuximab + chemoradiotherapy | 62 | NR | NR | NR | 51 | 3 | Pneumonia |
| Â | Â | Â | Chemoradiotherapy | 63 | NR | NR | NR | 51 | 0 | |
Douillard J.Y. et al ./2010/III | CRC | 1183 | Panitumumab + FOLFOX4 | NR | 20 | 9.6 | 23.9 | 539 | 15 | Febrile neutropenia |
| Â | Â | Â | FOLFOX4 | NR | NR | 8.6 | 19.7 | 545 | 14 | |
Peeters M. et al./ 2010/III | CRC | 1186 | Panitumumab + FOLFIRI | NR | NR | 5.9 | 14.5 | 539 | 9 | Febrile neutropenia |
| Â | Â | Â | FOLFIRI | NR | NR | 3.9 | 12.5 | 540 | 16 | |
Seymour M. T. et al ./2013/III | CRC | 460 | Panitumumab + irinotecan | 64 | 12 | NR | 10.4 | 219 | 42 | Infections |
| Â | Â | Â | Irinotecan | 63 | 12 | NR | 10.5 | 218 | 22 | |
Vermorken J.B. et al ./2008/III | Head and neck cancer | 657 | Panitumumab + DDP + FU | 58 | 18.3 | 5.8 | 11.1 | 325 | 20 | Febrile neutropenia |
|  |  |  | DDP + FU | 59 | NR | 4.6 | 9 | 325 | 17 | |
Waddell T. et al ./2013/III | Esophagogastric cancer | 553 | Panitumumab + epirubicin + oxaliplatin + capecitabine | 63 | 15 | 7.4 | 8.8 | 276 | 48 | Infection, febrile neutropenia |
|  |  |  | Epirubicin + oxaliplatin + capecitabine | 62 | 15 | 6 | 11.3 | 266 | 70 |